Furthermore, the percentage of individuals having a rSBA of ≥ 1:8 had fallen from 92% 4-6 weeks after vaccinations to 57% 6 months after immunization with Menjugate®, with the corresponding 4-6 week and 6 month data being 91% and 75% for Meningitec™ and 100% and 86% for NeisVac-C®.Menjugate is the vaccine used in Canada. These are all for
(
Read more... )
Comments 4
Reply
Reply
Reply
Reply
Leave a comment